Organon Korea's Cozaar XQ will be resupplied

at the end of this month

Original product for Losartan can be reproduced and prescribed in early February.

 

Organon's HTN treatment Cozaar XQ, which was suspended due to detection of impurities above the standard last year, will be resupplied at the end of this month.

 

Organon (CEO Kim So-eun) announced on the 27th that it will be able to re-supply Cozaar XQ from the end of this month and prescribe it from early February.

 

Cozaar XQ, the original product, was suspended from shipping after an impurity test conducted in November last year detected more than the standard level.

 

No impurities were detected in the same Losartan, Cozaar and Cozaar Plus.

 

Organon replaced Cozaar XQ with French raw materials such as Cozaar and Cozaar Plus to reproduce.

 

Normal products will begin to be supplied at the end of this month.

 

An official from Organon said, "The Coza family, such as Cozaar and Cozaar Plus, is an original Losartan distributed through strict quality management systems and demanding production processes by global pharmaceutical companies Organon, and Cozaar also produced Azido with undetected original Losartan." Organon added that it is making every effort to be prescribed without a hitch from February through the rapid supply and demand of Cozaar XQ.

 

In addition, the symposium Re-launching Cozaar XQ will be held in six cities in Seoul, Suwon, Daegu, Daejeon, Busan and Gwangju from February to March.

 

Along with the results of non-detection of impurities in the Cozaar family, Organon plans to emphasize initial therapy in patients with second stage hypertension who need to be administered with a combination to reach their treatment target blood pressure.